Bionamic

Bionamic specializes in providing software solutions tailored for the biologic drug development sector, focusing on antibody discovery and cloning management. The company offers a modular platform that integrates various stages of the drug development process, ensuring full traceability and seamless data management. Bionamic's tools facilitate the fast and reproducible identification of binders from screening data, allowing researchers to connect results from downstream sequencing and characterization assays. The platform supports the management of cloning processes, enabling users to track the origin of binders and constructs, and to swap between different binder formats such as scFv, Fab, and monoclonal. Additionally, Bionamic provides sequence analysis capabilities, allowing users to upload ABIF files and perform custom searches using CDR-based alignment tools. The company's business model likely involves licensing its software to pharmaceutical companies and research institutions engaged in antibody drug development, generating revenue through software subscriptions or usage fees. Bionamic operates in the biotechnology and pharmaceutical markets, serving clients who require advanced tools for managing complex research questions in antibody development.

Keywords: biologic, drug development, antibody, discovery, cloning, sequencing, binders, modular, platform, pharmaceutical